Immediate and long-term outcomes of percutaneous transcatheter pulmonary valve implantation

Fiszer, Roland; Dryżek, Paweł; Szkutnik, Małgorzata; Góreczny, Sebastian; Krawczuk, A.; Moll, Jadwiga; Moszura, Tomasz; Pawlak, Szymon; Białkowski, Jacek

doi:10.5603/cj.a2017.0023

Cited by 19 publications

(6 citation statements)

References 24 publications

(53 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All implantation procedures were successful -44 Melody and two Edwards systems were used. The study concluded that PPVI is a safe procedure with encouraging results, and it enables deferment of surgical reintervention in the majority of patients with right ventricular outflow tract dysfunction [5].…”

Section: Percutaneous Pulmonary Valve Implantation (Ppvi)mentioning

confidence: 94%

Progress in the interventional treatment of congenital and structural heart defects — scientific award of the Polish Cardiac Society

Białkowski

2019

Kardiol Pol

Self Cite

View full text Add to dashboard Cite

Section: Percutaneous Pulmonary Valve Implantation (Ppvi)mentioning

confidence: 94%

Progress in the interventional treatment of congenital and structural heart defects — scientific award of the Polish Cardiac Society

Białkowski

2019

Kardiol Pol

Self Cite

View full text Add to dashboard Cite

“…After a full-text review, 388 studies were excluded primarily because they did not focus on the clinical outcomes or necessary data were unavailable; the remaining 20 studies were included. [20][21][22][23][24][25][26][27][28][29][30][31][32][33][34][35][36][37][38][39] The study selection is shown in Figure 1.…”

Section: Study Selectionmentioning

confidence: 99%

“…Cardiac structure and function indices RVOT. The mean differences of the Doppler RVOT gradient after PPVI in eight studies 21,23,24,26,[29][30][31]35 are shown in Figure 2(a). A significant reduction of RVOT gradient was observed in the patients after PPVI (WMD = −19.63 mmHg; 95% CI: −21.15, −18.11; p < 0.001).…”

Section: Study Characteristicsmentioning

confidence: 99%

Percutaneous pulmonary valve implantation in patients with right ventricular outflow tract dysfunction: a systematic review and meta-analysis

Ran

Wang

Secchi

et al. 2019

Therapeutic Advances in Chronic Disease

View full text Add to dashboard Cite

Background: Pulmonary valve replacement is required for patients with right ventricular outflow tract (RVOT) dysfunction. Surgical and percutaneous pulmonary valve replacement are the treatment options. Percutaneous pulmonary valve implantation (PPVI) provides a less-invasive therapy for patients. The aim of this study was to evaluate the effectiveness and safety of PPVI and the optimal time for implantation. Methods: We searched PubMed, EMBASE, Clinical Trial , and Google Scholar databases covering the period until May 2018. The primary effectiveness endpoint was the mean RVOT gradient; the secondary endpoints were the pulmonary regurgitation fraction, left and right ventricular end-diastolic and systolic volume indexes, and left ventricular ejection fraction. The safety endpoints were the complication rates. Results: A total of 20 studies with 1246 participants enrolled were conducted. The RVOT gradient decreased significantly [weighted mean difference (WMD) = −19.63 mmHg; 95% confidence interval (CI): −21.15, −18.11; p < 0.001]. The right ventricular end-diastolic volume index (RVEDVi) was improved (WMD = −17.59 ml/m²; 95% CI: −20.93, −14.24; p < 0.001), but patients with a preoperative RVEDVi >140 ml/m² did not reach the normal size. Pulmonary regurgitation fraction (PRF) was notably decreased (WMD = −26.27%, 95% CI: −34.29, −18.25; p < 0.001). The procedure success rate was 99% (95% CI: 98–99), with a stent fracture rate of 5% (95% CI: 4–6), the pooled infective endocarditis rate was 2% (95% CI: 1–4), and the incidence of reintervention was 5% (95% CI: 4–6). Conclusions: In patients with RVOT dysfunction, PPVI can relieve right ventricular remodeling, improving hemodynamic and clinical outcomes.

show abstract

“…Developments in percutaneous pulmonary valve technology have expanded rapidly in the last 10 years 1–8 . The most recent focus has been on the major area of unmet need, the large regurgitant “native” outflow tract 9–16 .…”

Section: Introductionmentioning

confidence: 99%

Early clinical experience with the straight design of Venus P‐valve™ in dysfunctional right ventricular outflow tracts

Morgan

Sivakumar

Promphan

et al. 2020

Cathet Cardio Intervent

View full text Add to dashboard Cite

Objectives: To assess the initial procedural and short to medium-term experience with the straight design of the Venus P-valve™ (Venus MedTech, Hangzhou, China) in dysfunctional right ventricular outflow tracts (RVOT). Background: The Melody™ valve (Medtronic, Minneapolis, Minnesota) has been the only percutaneous valve option for smaller RVOT conduits. The straight Venus P-valve™ may provide an alternative to the Melody™ valve. Methods: Retrospective data collection of patient characteristics, procedural data, clinical and imaging follow-up of the straight Venus P-valve™. Results: Nine patients (four female) with a mean age of 23.1 ± 7.5 years and a mean weight of 72.7 ± 29.4 kg underwent straight Venus P-valve™ implantation between 03/2014 and 06/2016. All patients had right ventricle-to-pulmonary artery conduits which were pre-stented before the valve implantation. All valves were deployed successfully without any significant procedural complications. During the mean followup of 24 ± 9.1 months, there were no valve related re-interventions or deterioration in valve performance. There was one case of insignificant, single wire frame fracture and no cases of endocarditis. The cohort demonstrated a reduction in pulmonary regurgitation and tricuspid regurgitation, which was sustained throughout the followup. Similarly the gradient across the RVOT tract did not significantly increase. Conclusions: Implantation of the straight Venus P-valve™ has provided satisfactory short to mid-term results with high success rates and no complications and may be considered as an alternative option in patients with RVOT dysfunction. K E Y W O R D S congenital heart disease, percutaneous intervention, transcatheter pulmonary valve 1 | INTRODUCTION Developments in percutaneous pulmonary valve technology have expanded rapidly in the last 10 years. 1-8 The most recent focus has been on the major area of unmet need, the large regurgitant "native" outflow tract. 9-16 This expansion has combined the development of innovative techniques to apply currently available

show abstract

Immediate and long-term outcomes of percutaneous transcatheter pulmonary valve implantation

Abstract: (Cardiol J 2017; 24, 6: 604-611)

Cited by 19 publications

References 24 publications

Progress in the interventional treatment of congenital and structural heart defects — scientific award of the Polish Cardiac Society

Progress in the interventional treatment of congenital and structural heart defects — scientific award of the Polish Cardiac Society

Percutaneous pulmonary valve implantation in patients with right ventricular outflow tract dysfunction: a systematic review and meta-analysis

Early clinical experience with the straight design of Venus P‐valve™ in dysfunctional right ventricular outflow tracts

Contact Info

Product

Resources

About